Study objective: The standard daily dose of rifampin in directly observed treatment of Mycobacterium tuberculosis (TB) is 600 mg, taken orally. The purpose of this study was to assess the efficacy of standard dose rifampin therapy in patients who were slow to respond to routine directly observed therapy (DOT). Methods: Patients with non-drug-resistant pulmonary TB who were receiving 600 mg of oral rifampin by DOT were eligible for inclusion. Patients were deemed slow to respond if their sputum smears and cultures remained positive for M tuberculosis and if the patient’s condition did not improve clinically or radiographically after 3 months of treatment. Serum rifampin levels were ascertained to determine the adequacy of the standard rifampin dosing. Patients with subtherapeutic blood levels had their rifampin dose increased to 900 mg, and rifampin levels were repeated. Rifampin dosage was increased again if blood levels were still subtherapeutic. No antitubercular medications were added to the treatment regimen. The total weekly dose of the other standard treatment drugs was not increased. Results: Of 124 new patients with active pulmonary TB, 6 patients were identified as slow to respond to the standard antitubercular DOT. All six patients had subtherapeutic serum rifampin levels. All six patients responded clinically, radiographically, and mycobacteriologically after an increase in rifampin dosage to reach target drug blood level. Conclusions: Standard dosing with rifampin resulted in a poor clinical response and subtherapeutic serum levels in six patients. Increasing the dosage of rifampin improved the outcome without additional side effects. In TB patients who are slow to respond to standard treatment, an inadequate dose of rifampin should be suspected. Current antituberculer drug administration does not include adjusted dosage for rifampin.

Thesis (M.Sc. (Pharmacology))--North-West University, Potchefstroom Campus, 2009.

Selective antiretroviral! (ARV) drugs are primarily metabolized by cytochrome P450 (CYP) enzymes, characteristically predisposed to variation, and are therefore primarily responsible for ARV pharmacokinetic variability and associated drug interactions. For the majority of ARV drugs, the therapeutic window is narrow and imminent toxicities due to CYP inhibition or sub-therapeutic drug levels as a result of CYP induction is inevitable. Animals provide a metabolism replica to conduct detailed investigations. We endeavored to establish a rat model to screen for variability in metabolism of selective ARV drugs responsible for treatment failure and drug interactions, over time in the liver and serum. Male Sprague-Dawley rats (n = 24) were divided into 6 groups: methylcellulose, 160mg/kg/day (n = 24) (control); efavirenz, 160mg/kg/day (n = 18); ritonavir, 20 mg/kg/day (n = 18); ritonavir, 20 mg/kg/day and verapamil 5 mg/kg/day (n = 18); Kaletra® (ritonavir/lopinavir), 20 mg/kg/day, (n = 18); Kaletra® (ritonavir/lopinavir), 20 mg/kg/day and verapamil 5 mg/kg/day (n = 18). Treatment duration varied from one day (single dose), 7 or 21 days. Blood samples were collected after decapitation on days 1, 7 and 21. A sensitive and rapid liquid chromatograph (LC) interfaced to a quadrupoie mass spectrometer (MS) and coupled with electrospray ionization (ESI) method was employed for the blood sample determinations. One single injection was required to simultaneously quantify efavirenz, lopinavir and ritonavir within the linear concentration range of 78 - 5000 ng/ml. Efavirenz blood levels increased statistically significantly (p < 0.05) from day 1 to day 21 with distinct steady state achievement prior to day 7. The levels of ritonavir increased statistically significantly (p < 0.05) from day 7 to 21 when administered alone and statistically significantly (p < 0.01) from day 1 to 21 when administered as the ritonavir/lopinavir combination. The levels of lopinavir also increased statistically significantly (p<0.01) from day 1 and 21 in the ritonavir/lopinavir combination. However, the inclusion of a P-glycoprotein inhibitor, verapamil, increased both the ritonavir (administered alone) and lopinavir blood levels significantly (p < 0.05) at day 1. The ritonavir levels were also significantly increased on day 21 (p < 0.05). When verapamil was added to the ritonavir/lopinavir combination the levels of ritonavir increased statistically significantly (p < 0.01) from day 1 to 21. A rat model can be used to detect changes in metabolism over time as measured by blood levels. The influence of drug interactions, such as verapamil, on ARV drug metabolism can be investigated by this model. These results will be substantiated by PCR liver results in the future. / Thesis (M.Sc. (Pharmacology))--North-West University, Potchefstroom Campus, 2009.

Selective antiretroviral! (ARV) drugs are primarily metabolized by cytochrome P450 (CYP) enzymes, characteristically predisposed to variation, and are therefore primarily responsible for ARV pharmacokinetic variability and associated drug interactions. For the majority of ARV drugs, the therapeutic window is narrow and imminent toxicities due to CYP inhibition or sub-therapeutic drug levels as a result of CYP induction is inevitable. Animals provide a metabolism replica to conduct detailed investigations. We endeavored to establish a rat model to screen for variability in metabolism of selective ARV drugs responsible for treatment failure and drug interactions, over time in the liver and serum. Male Sprague-Dawley rats (n = 24) were divided into 6 groups: methylcellulose, 160mg/kg/day (n = 24) (control); efavirenz, 160mg/kg/day (n = 18); ritonavir, 20 mg/kg/day (n = 18); ritonavir, 20 mg/kg/day and verapamil 5 mg/kg/day (n = 18); Kaletra® (ritonavir/lopinavir), 20 mg/kg/day, (n = 18); Kaletra® (ritonavir/lopinavir), 20 mg/kg/day and verapamil 5 mg/kg/day (n = 18). Treatment duration varied from one day (single dose), 7 or 21 days. Blood samples were collected after decapitation on days 1, 7 and 21. A sensitive and rapid liquid chromatograph (LC) interfaced to a quadrupoie mass spectrometer (MS) and coupled with electrospray ionization (ESI) method was employed for the blood sample determinations. One single injection was required to simultaneously quantify efavirenz, lopinavir and ritonavir within the linear concentration range of 78 - 5000 ng/ml. Efavirenz blood levels increased statistically significantly (p < 0.05) from day 1 to day 21 with distinct steady state achievement prior to day 7. The levels of ritonavir increased statistically significantly (p < 0.05) from day 7 to 21 when administered alone and statistically significantly (p < 0.01) from day 1 to 21 when administered as the ritonavir/lopinavir combination. The levels of lopinavir also increased statistically significantly (p<0.01) from day 1 and 21 in the ritonavir/lopinavir combination. However, the inclusion of a P-glycoprotein inhibitor, verapamil, increased both the ritonavir (administered alone) and lopinavir blood levels significantly (p < 0.05) at day 1. The ritonavir levels were also significantly increased on day 21 (p < 0.05). When verapamil was added to the ritonavir/lopinavir combination the levels of ritonavir increased statistically significantly (p < 0.01) from day 1 to 21. A rat model can be used to detect changes in metabolism over time as measured by blood levels. The influence of drug interactions, such as verapamil, on ARV drug metabolism can be investigated by this model. These results will be substantiated by PCR liver results in the future. / Thesis (M.Sc. (Pharmacology))--North-West University, Potchefstroom Campus, 2009.

CoordenaÃÃo de AperfeiÃoamento de NÃvel Superior / A infecÃÃo pelo Helicobacter pylori à uma das infecÃÃes mais prevalentes do mundo. Existem fortes evidÃncias de que a transmissÃo dessa bactÃria ocorre na infÃncia, e estudos epidemiolÃgicos em crianÃas sÃo essenciais para que se entenda os aspectos relacionados com a dinÃmica da infecÃÃo e suas conseqÃÃncias. Previamente pesquisadores vinculados ao LaboratÃrio de Gastroenterologia da Universidade Federal do Cearà avaliaram a prevalÃncia de H.pylori em crianÃas atà quatorze anos de idade em uma comunidade fixa de baixa renda, denominada Parque UniversitÃrio. No presente estudo, foi realizado outro corte transversal aproximadamente oito anos apÃs a anÃlise inicial nesse mesmo grupo de crianÃas, com o objetivo de avaliar a dinÃmica da infecÃÃo e se as crianÃas infectadas sÃo mais susceptÃveis a terem anemia, deficiÃncia de ferrritina, folato e vitamina B12 do que as nÃo infectadas. A infecÃÃo por H. pylori foi avaliada em 133 crianÃas por meio do teste respiratÃrio, previamente validado para a populaÃÃo brasileira. Foram coletadas amostras de sangue em 108 crianÃas para a realizaÃÃo de hemograma e a dosagem de concentraÃÃes sÃricas de ferritina, vitamina B12 e folato por meio da tÃcnica de quimioluminescencia utilizando Immulite  2000. A prevalÃncia da infecÃÃo por H. pylori nas crianÃas foi de 53,4% (71/133) em 2000, enquanto a prevalÃncia de H. pylori nas mesmas crianÃas em 2008 foi de 64,7% (86/133). ApÃs 8 anos, a maioria (88,7%) das crianÃas H. pylori positivas permaneceram infectadas. A taxa de aquisiÃÃo da infecÃÃo por H. pylori apÃs 8 anos da anÃlise inicial foi de 17,3% (23/133) e a taxa de cura espontÃnea da infecÃÃo foi de 6% (8/133). As taxas de aquisiÃÃo foram maiores em crianÃas com idade de 10 anos ou menos, atingindo 30,2% em crianÃas menores de 5 anos. A prevalÃncia da infecÃÃo em crianÃas com menos de 5 anos aumentou de 39.6% em 2000 para 62,2% em 2008 (p=0,020). NÃo houve diferenÃa estatisticamente significante entre anemia, concentraÃÃes sÃricas de ferritina, vitamina B12 e folato em indivÃduos H. pylori positivos comparados aos H. pylori negativos. Em conclusÃo, a infecÃÃo por H. pylori à adquirida precocemente na infÃncia, com altas taxas de aquisiÃÃo em crianÃas com 10 anos ou menos. NÃo foi encontrado associaÃÃo entre a infecÃÃo por H. pylori e anemia, nÃveis sÃricos de vitamina B12, ferritina e folato / A infecÃÃo pelo Helicobacter pylori à uma das infecÃÃes mais prevalentes do mundo. Existem fortes evidÃncias de que a transmissÃo dessa bactÃria ocorre na infÃncia, e estudos epidemiolÃgicos em crianÃas sÃo essenciais para que se entenda os aspectos relacionados com a dinÃmica da infecÃÃo e suas conseqÃÃncias. Previamente pesquisadores vinculados ao LaboratÃrio de Gastroenterologia da Universidade Federal do Cearà avaliaram a prevalÃncia de H.pylori em crianÃas atà quatorze anos de idade em uma comunidade fixa de baixa renda, denominada Parque UniversitÃrio. No presente estudo, foi realizado outro corte transversal aproximadamente oito anos apÃs a anÃlise inicial nesse mesmo grupo de crianÃas, com o objetivo de avaliar a dinÃmica da infecÃÃo e se as crianÃas infectadas sÃo mais susceptÃveis a terem anemia, deficiÃncia de ferrritina, folato e vitamina B12 do que as nÃo infectadas. A infecÃÃo por H. pylori foi avaliada em 133 crianÃas por meio do teste respiratÃrio, previamente validado para a populaÃÃo brasileira. Foram coletadas amostras de sangue em 108 crianÃas para a realizaÃÃo de hemograma e a dosagem de concentraÃÃes sÃricas de ferritina, vitamina B12 e folato por meio da tÃcnica de quimioluminescencia utilizando Immulite  2000. A prevalÃncia da infecÃÃo por H. pylori nas crianÃas foi de 53,4% (71/133) em 2000, enquanto a prevalÃncia de H. pylori nas mesmas crianÃas em 2008 foi de 64,7% (86/133). ApÃs 8 anos, a maioria (88,7%) das crianÃas H. pylori positivas permaneceram infectadas. A taxa de aquisiÃÃo da infecÃÃo por H. pylori apÃs 8 anos da anÃlise inicial foi de 17,3% (23/133) e a taxa de cura espontÃnea da infecÃÃo foi de 6% (8/133). As taxas de aquisiÃÃo foram maiores em crianÃas com idade de 10 anos ou menos, atingindo 30,2% em crianÃas menores de 5 anos. A prevalÃncia da infecÃÃo em crianÃas com menos de 5 anos aumentou de 39.6% em 2000 para 62,2% em 2008 (p=0,020). NÃo houve diferenÃa estatisticamente significante entre anemia, concentraÃÃes sÃricas de ferritina, vitamina B12 e folato em indivÃduos H. pylori positivos comparados aos H. pylori negativos. Em conclusÃo, a infecÃÃo por H. pylori à adquirida precocemente na infÃncia, com altas taxas de aquisiÃÃo em crianÃas com 10 anos ou menos. NÃo foi encontrado associaÃÃo entre a infecÃÃo por H. pylori e anemia, nÃveis sÃricos de vitamina B12, ferritina e folato / Helicobacter pylori infection is one the most prevalent infections in the world. There is a strong evidence that it is acquired in childhood. Therefore epidemiological studies in children are essential to understand the dynamics of this infection and also to evaluate the possible consequences of H. pylori infection in children. Previously it was evaluated the prevalence of H. pylori in children up to fourteen years of age at a low-income community called Parque UniversitÃrio. The present study is a cohort of a group of children eight years after the first study, with the aim of evaluating the dynamics of H. pylori infection and also to check if infected children are more likely to have anemia and ferrritin, folate and vitamin B12 deficiency when compared to non-infected children. The infection was evaluated in 133 individuals through the 13C urea breath test, previously validated for the brazilian population. Blood was sampled from 108 individuals to dose levels of ferritin, vitamin B12 and folate by chemiluminescence using Immulite  2000 and hemoglobin. The prevalence of H. pylori infection in the individuals was 53.4% (71/133) in 2000, while the prevalence of H. pylori in the same group in 2008 was 64.7% (86/133). It was found that after eight years, the majority (88.7%) of H. pylori positive individuals remained positive for infection. The rate of acquisition of infection by H. pylori after 8 years of the initial analysis was 17.3% (23/133) and the rate of loss of infection was 6% (8/133). The acquisition rates were higher in children younger than 10 years, reaching 30.2% in children younger than 5 years. The prevalence of infection in children under 5 years increased from 39.6% in 2000 to 62.2% in 2008 (p = 0.020). There was no statistically significant difference between anemia, serum ferritin, vitamin B12 and folate in H. pylori-positive individuals compared to H. pylori-negative. In conclusion, H. pylori infection is acquired early in childhood, with high rates of acquisition in children under 10 years. There was no association between H. pylori infection and anemia, serum vitamin B12 and folate levels among the individuals studied. / Helicobacter pylori infection is one the most prevalent infections in the world. There is a strong evidence that it is acquired in childhood. Therefore epidemiological studies in children are essential to understand the dynamics of this infection and also to evaluate the possible consequences of H. pylori infection in children. Previously it was evaluated the prevalence of H. pylori in children up to fourteen years of age at a low-income community called Parque UniversitÃrio. The present study is a cohort of a group of children eight years after the first study, with the aim of evaluating the dynamics of H. pylori infection and also to check if infected children are more likely to have anemia and ferrritin, folate and vitamin B12 deficiency when compared to non-infected children. The infection was evaluated in 133 individuals through the 13C urea breath test, previously validated for the brazilian population. Blood was sampled from 108 individuals to dose levels of ferritin, vitamin B12 and folate by chemiluminescence using Immulite  2000 and hemoglobin. The prevalence of H. pylori infection in the individuals was 53.4% (71/133) in 2000, while the prevalence of H. pylori in the same group in 2008 was 64.7% (86/133). It was found that after eight years, the majority (88.7%) of H. pylori positive individuals remained positive for infection. The rate of acquisition of infection by H. pylori after 8 years of the initial analysis was 17.3% (23/133) and the rate of loss of infection was 6% (8/133). The acquisition rates were higher in children younger than 10 years, reaching 30.2% in children younger than 5 years. The prevalence of infection in children under 5 years increased from 39.6% in 2000 to 62.2% in 2008 (p = 0.020). There was no statistically significant difference between anemia, serum ferritin, vitamin B12 and folate in H. pylori-positive individuals compared to H. pylori-negative. In conclusion, H. pylori infection is acquired early in childhood, with high rates of acquisition in children under 10 years. There was no association between H. pylori infection and anemia, serum vitamin B12 and folate levels among the individuals studied.

Este trabalho teve como objetivo avaliar o efeito da aplicação do ultra-som (US) de 1 MHz comparando as freqüências de repetição de pulso de 100 Hz e 16 Hz na recuperação da fratura de fíbula, por análise morfológica e bioquímica, entre animais tratados e não-tratados. Foram utilizados 60 ratos machos albinos Wistar divididos em 4 grupos experimentais: referência, controle, tratados com US com freqüência de repetição de pulso de 16 Hz ou 100 Hz. Os animais dos grupos tratado e controle foram submetidos a uma fratura com perda óssea da fíbula direita. O tratamento teve início 24 h após a fratura, durante 5 dias por semana, com intensidade de 0,5 W/'CM POT.2', modo pulsado 1/5, freqüência de repetição de pulso a 100 Hz ou 16 Hz, por 3 min/dia. No 7°, 14º e 21º dia após a indução da fratura foi realizada coleta do sangue através de punção cardíaca para quantificação dos níveis de fosfatase alcalina e cálcio sérico e em seguida os animais foram submetidos à eutanásia e a fíbula foi removida para análise histológica. Foram determinadas a densidade de matriz óssea, condrócitos e fibroblastos. Os níveis de fosfatase alcalina e cálcio foram significativamente (P < '10 POT.-7') diferentes nos grupos experimentais. A densidade de matriz óssea, condrócitos e fibroblastos também foram significativamente diferentes entre os grupos experimentais. O tratamento com US acelerou a regeneração óssea e modulou os níveis sanguíneos de fosfatase alcalina e cálcio, sendo que, o US pulsado com freqüência de repetição de pulso a 100 Hz e freqüência de base da 1 MHz demonstrou ser mais eficaz / The aim of this work was to evaluate the effect of 1 MHz ultrasound application, comparing the 100 Hz and 16 Hz pulse repetition frequency in the recovering of fibula fracture, using morphological and biochemical analysis, between treated and non-treated animals. We used 60 male albino Wistar rats divided into 4 experimental groups: reference; control; treated with 100 Hz or 16 Hz pulse repetition frequency ultrasound. The treatment began 24 h after fracturing, lasted for 5 days per week, with 0.5 W/'CM POT. 2', pulsed mode 1/5, pulse repetition frequency of 100 Hz or 16 Hz, for 3 min a day. In the 7th, 14th and 21st after fracture induction, blood was collected through cardiac punction to alkaline phosphatase and calcium levels quantification and following that, the animals were euthanised and the fibula was removed to histological analysis. The bone matrix, condrocytes and fibroblasts densityes were determined. The levels of alkaline phosphatase and calcium were significantly (P < '10 POT.-7') different among the experimental group. The bone matrix, condrocytes and fibroblasts densities were significantly different among experimental groups. The US treatment accelerated the bone regeneration and modulated the alkaline phosphatase and calcium blood levels, being the pulsed US with 100 Hz pulse repetition frequency and base current 1 MHz the most efficient

Dissertação(mestrado)- Universidade Federal do Rio Grande, Programa de Pós-Graduação em Engenharia e Ciência de Alimentos, Escola de Química e Alimentos, 2010. / Submitted by Caroline Silva (krol_bilhar@hotmail.com) on 2012-08-15T21:29:59Z No. of bitstreams: 1 dissertao.final.lidiane.pdf: 1460415 bytes, checksum: 6f8a2a7217fb18e07210cc2a3ead7b12 (MD5) / Approved for entry into archive by Bruna Vieira(bruninha_vieira@ibest.com.br) on 2012-09-03T19:03:03Z (GMT) No. of bitstreams: 1 dissertao.final.lidiane.pdf: 1460415 bytes, checksum: 6f8a2a7217fb18e07210cc2a3ead7b12 (MD5) / Made available in DSpace on 2012-09-03T19:03:03Z (GMT). No. of bitstreams: 1 dissertao.final.lidiane.pdf: 1460415 bytes, checksum: 6f8a2a7217fb18e07210cc2a3ead7b12 (MD5) Previous issue date: 2010 / Spirulina é uma cianobactéria que vem sendo produzida e estudada devido suas propriedades nutricionais e benéficas à saúde. Atualmente, a Legislação brasileira recomenda, como limite máximo de consumo diário por pessoa, 1,6g de Spirulina (BRASIL, 2009). O presente trabalho tem como objetivo geral avaliar o efeito de dietas adicionadas de diferentes concentrações de Spirulina LEB-18 sobre os perfis bioquímicos, hematológicos, nutricionais e fisiológicos de ratos machos da linhagem Rattus norvegicus cepa Wistar/UFPel. Atendendo todas as necessidades bioclimatológicas, tanto de micro como macro ambientes, o bioensaio, aprovado pela Comissão de Ética da Universidade Federal de Pelotas – UFPel (processo nº 23110. 008077/2009-22) foi conduzido na Sala de Experimentação Animal do Departamento de Ciência dos Alimentos da UFPel. O experimento foi realizado durante 45 dias, sendo os 5 primeiros para adaptação dos animais ao ambiente e à dieta controle e os demais para a realização, em paralelo, de dois experimentos (I e II). No experimento “I”, com duração de 40 dias, os animais (n=24) foram distribuídos em 4 tratamentos, conforme dieta ofertada: C (caseína como fonte protéica); S1 (1,6g Spirulina/dia); S2 (3,2g Spirulina/dia); e S3 (4,8g Spirulina/dia). No experimento II, durante 10 dias, os animais (n=23) receberam uma dieta aprotéica (A). Posteriormente foram redistribuídos em 4 grupos (C, S1, S2 e S3) para recuperação nutricional durante 30 dias. No decorrer e ao término do experimento foram observados peso dos animais e ingestão diária de dieta; coletados materiais biológicos, como, excretas, sangue e órgãos para posteriores determinações. Dentre as concentrações estudadas, a S1, caracterizada pelo limite descrito pela ANVISA, apresentou melhores resultados. Apesar de algumas diferenças entre os tratamentos adicionados de Spirulina, a microalga mostrou-se eficaz ao desenvolvimento dos animais e não causou reações adversas, conforme determinações, condições e período de realização desta pesquisa. / Spirulina is a cyanobacteria that has been produced and studied for its nutritional properties and health benefits. Presently, Brazilian legislation recommends a maximum consumption limit of 1.6g of Spirulina daily per person (BRAZIL, 2009). This study has the general objective of evaluating the effect of diets supplemented with different concentrations of Spirulina LEB-18 on biochemical profiles, hematologic, nutritional and physiological characteristics of male rats of the classification Rattus norvegicus strain Wistar/UFPel. Given all the bioclimatological needs, both micro and macro environments, the bio-assay, approved by the Ethics Committee of Pelotas Federal University (UFPEL) (processo nº 23110. 008077/2009-22), was conducted in the Hall of Animal Experimentation at the Department of Food Science, UFPEL. The study was carried out over 45 days, with the first 5 days for the adaptation of the animals to the environemnt and dietary control. Over the remaining 40 days, two experiments (I and II) were carried out in parallel. In experiment “I”, lasting 40 days, the animals (n=24) were distributed into the following 4 groups of diet preparation offered: C (casein as a protein source); S1 (1,6g Spirulina/day); S2 (3,2g Spirulina/day); and S3 (4,8g Spirulina/day). In experiment “II”, lasting 10 days, the animals (n=23) received an aproteic diet (A). Afterwards, they were distributed into four groups offered the diet preparations C, S1, S2 and S3 cited above, for nutritional recovery lasting 30 days. In the course of the experiment and at the end, animal weight and daily dietary intake were observed; biological materials, (such as feces, blood and organs), were collected for subsequent analysis. Amongst the concentrations studied, the S1 group, characterised by the limit described by ANVISA, showed better results. Despite some differences amongst the groups, supplementation with Spirulina microalgae proved effective for animal development and caused no adverse reactions, as prescribed within the conditions and duration of this research.

Este trabalho teve como objetivo avaliar o efeito da aplicação do ultra-som (US) de 1 MHz comparando as freqüências de repetição de pulso de 100 Hz e 16 Hz na recuperação da fratura de fíbula, por análise morfológica e bioquímica, entre animais tratados e não-tratados. Foram utilizados 60 ratos machos albinos Wistar divididos em 4 grupos experimentais: referência, controle, tratados com US com freqüência de repetição de pulso de 16 Hz ou 100 Hz. Os animais dos grupos tratado e controle foram submetidos a uma fratura com perda óssea da fíbula direita. O tratamento teve início 24 h após a fratura, durante 5 dias por semana, com intensidade de 0,5 W/'CM POT.2', modo pulsado 1/5, freqüência de repetição de pulso a 100 Hz ou 16 Hz, por 3 min/dia. No 7°, 14º e 21º dia após a indução da fratura foi realizada coleta do sangue através de punção cardíaca para quantificação dos níveis de fosfatase alcalina e cálcio sérico e em seguida os animais foram submetidos à eutanásia e a fíbula foi removida para análise histológica. Foram determinadas a densidade de matriz óssea, condrócitos e fibroblastos. Os níveis de fosfatase alcalina e cálcio foram significativamente (P < '10 POT.-7') diferentes nos grupos experimentais. A densidade de matriz óssea, condrócitos e fibroblastos também foram significativamente diferentes entre os grupos experimentais. O tratamento com US acelerou a regeneração óssea e modulou os níveis sanguíneos de fosfatase alcalina e cálcio, sendo que, o US pulsado com freqüência de repetição de pulso a 100 Hz e freqüência de base da 1 MHz demonstrou ser mais eficaz / The aim of this work was to evaluate the effect of 1 MHz ultrasound application, comparing the 100 Hz and 16 Hz pulse repetition frequency in the recovering of fibula fracture, using morphological and biochemical analysis, between treated and non-treated animals. We used 60 male albino Wistar rats divided into 4 experimental groups: reference; control; treated with 100 Hz or 16 Hz pulse repetition frequency ultrasound. The treatment began 24 h after fracturing, lasted for 5 days per week, with 0.5 W/'CM POT. 2', pulsed mode 1/5, pulse repetition frequency of 100 Hz or 16 Hz, for 3 min a day. In the 7th, 14th and 21st after fracture induction, blood was collected through cardiac punction to alkaline phosphatase and calcium levels quantification and following that, the animals were euthanised and the fibula was removed to histological analysis. The bone matrix, condrocytes and fibroblasts densityes were determined. The levels of alkaline phosphatase and calcium were significantly (P < '10 POT.-7') different among the experimental group. The bone matrix, condrocytes and fibroblasts densities were significantly different among experimental groups. The US treatment accelerated the bone regeneration and modulated the alkaline phosphatase and calcium blood levels, being the pulsed US with 100 Hz pulse repetition frequency and base current 1 MHz the most efficient

Un modèle pharmacocinétique à base physiologique (PBPK) d’exposition par inhalation à l’éthanol a antérieurement été développé en se basant sur des données provenant d’une étude chez des volontaires exposés par inhalation à plus de 5000 ppm. Cependant, une incertitude persiste sur la capacité du modèle PBPK à prédire les niveaux d’éthanolémie pour des expositions à de faibles concentrations. Ces niveaux sont fréquemment rencontrés par une large partie de la population et des travailleurs suite à l’utilisation de produits tels que les vernis et les solutions hydroalcooliques (SHA). Il est ainsi nécessaire de vérifier la validité du modèle existant et de déterminer l’exposition interne à l’éthanol dans de telles conditions. Les objectifs du mémoire sont donc 1) de documenter les niveaux d’éthanolémie résultant de l’exposition par inhalation à de faibles concentrations d’éthanol (i.e., ≤ 1000 ppm) et de valider/raffiner le modèle PBPK existant pour ces concentrations ; et 2) de déterminer les concentrations d’éthanol atmosphérique provenant d’utilisation de SHA et de vernis et de prédire les niveaux d’éthanolémie découlant de leur utilisation. Les données toxicocinétiques récoltées chez des volontaires nous suggèrent qu’il est insuffisant de limiter au foie la clairance métabolique de l’éthanol lors d’exposition à de faibles niveaux d’éthanol, contrairement aux expositions à de plus forts niveaux. De plus, il a clairement été démontré qu’un effort physique léger (50 W) influençait à la hausse (2-3 fois) l’éthanolémie des volontaires exposés à 750 ppm. L’ajout au modèle PBPK d’une clairance métabolique de haute affinité et de faible capacité associée aux tissus richement perfusés a permis de simuler plus adéquatement la cinétique de l’éthanolémie pour des expositions à des concentrations inférieures à 1000 ppm. Des mesures de concentrations d’éthanol dans l’air inhalé générées lors d’utilisation de SHA et de vernis ont permis de simuler des expositions lors de l’utilisation de ces produits. Pour l’utilisation de 1,5 g et 3 g de SHA dans un local peu ventilé, des concentrations sanguines maximales (Cmax) de 0.383 et 0.366 mg.L-1 ont été respectivement simulées. Dans un local bien ventilé, les Cmax simulées étaient de 0.264 et 0.414 mg.L-1. Selon les simulations, une application de vernis résulterait en une Cmax respectivement de 0.719 mg.L-1 et de 0.729 mg.L-1, chez les hommes et femmes. Les Cmax sanguines d’éthanol estimées suites aux différentes simulations sont inférieures à la concentration toxique pour les humains (100 mg.L-1). Ainsi, de telles expositions ne semblent pas être un danger pour la santé. Les résultats de cette étude ont permis de mieux décrire et comprendre les processus d’élimination de l’éthanol à faibles doses et permettront de raffiner l’évaluation du risque associé à l’inhalation chronique de faibles niveaux d’éthanol pour la population, particulièrement chez les travailleurs. / A physiologically based pharmacokinetic model (PBPK) on inhalation exposure to ethanol has previously been developed based on data from an inhalation study in volunteers exposed to more than 5000 ppm. However, there remains uncertainty about the ability of the PBPK model to predict the blood levels of ethanol (BLE) for exposure to low concentrations. These levels are frequently encountered by a large part of the population and workers by using products such as varnishes and alcoholic solutions (HAS). It is therefore necessary to verify the validity of the existing model and determine the internal exposure to ethanol in such conditions. The objectives of this master’s thesis are 1) to document the BLE resulting from inhalation exposure to low concentrations of ethanol (i.e., ≤ 1000 ppm) and validate/refine the existing PBPK model for these concentrations, and 2) to determine the atmospheric concentrations of ethanol following the use of alcoholic solutions (HAS) and varnish as well as to predict the BLE resulting from their use. Toxicokinetic data collected from volunteers suggest that it is insufficient to limit metabolic clearance of ethanol to the liver during exposures to low levels of ethanol, unlike exposures to stronger levels. In addition, it was clearly demonstrated that light exercise (50W) increased (2-3 fold) the BLE in volunteers exposed to 750 ppm. An addition to the PBPK model of a metabolic clearance of high affinity and low capacity associated with richly perfused tissue was performed to simulate more accurately the toxicokinetic data from low and high ethanol exposure levels. Measurements of ethanol concentrations in inhaled air generated during the use of HAS and varnishes were used to simulate the exposure during the use of these products. The simulation for HAS, for 1.5 g and 3 g, gave a maximum blood concentration (Cmax) of 0.383 and 0.366 mg.L-1 respectively in a poorly ventilated room. In a well-ventilated room, the simulated Cmax for 1.5 g and 3 g of HAS were 0.264 and 0.414 mg.L-1, respectively. The simulation results from the use of ethanol-based varnish yielded a Cmax for men and women of 0.719 and 0.729 mg.L-1 respectively. The blood Cmax of ethanol previously listed for the various simulations are well below the toxic dose for humans (50 mg.L-1). Thus, such exposures do not seem to be a health hazard. The results of this study helped to better describe and understand the elimination of ethanol at low doses and refine the evaluation process associated with chronic inhalation of low levels of ethanol to the population risk, particularly in workers.

Un modèle pharmacocinétique à base physiologique (PBPK) d’exposition par inhalation à l’éthanol a antérieurement été développé en se basant sur des données provenant d’une étude chez des volontaires exposés par inhalation à plus de 5000 ppm. Cependant, une incertitude persiste sur la capacité du modèle PBPK à prédire les niveaux d’éthanolémie pour des expositions à de faibles concentrations. Ces niveaux sont fréquemment rencontrés par une large partie de la population et des travailleurs suite à l’utilisation de produits tels que les vernis et les solutions hydroalcooliques (SHA). Il est ainsi nécessaire de vérifier la validité du modèle existant et de déterminer l’exposition interne à l’éthanol dans de telles conditions. Les objectifs du mémoire sont donc 1) de documenter les niveaux d’éthanolémie résultant de l’exposition par inhalation à de faibles concentrations d’éthanol (i.e., ≤ 1000 ppm) et de valider/raffiner le modèle PBPK existant pour ces concentrations ; et 2) de déterminer les concentrations d’éthanol atmosphérique provenant d’utilisation de SHA et de vernis et de prédire les niveaux d’éthanolémie découlant de leur utilisation. Les données toxicocinétiques récoltées chez des volontaires nous suggèrent qu’il est insuffisant de limiter au foie la clairance métabolique de l’éthanol lors d’exposition à de faibles niveaux d’éthanol, contrairement aux expositions à de plus forts niveaux. De plus, il a clairement été démontré qu’un effort physique léger (50 W) influençait à la hausse (2-3 fois) l’éthanolémie des volontaires exposés à 750 ppm. L’ajout au modèle PBPK d’une clairance métabolique de haute affinité et de faible capacité associée aux tissus richement perfusés a permis de simuler plus adéquatement la cinétique de l’éthanolémie pour des expositions à des concentrations inférieures à 1000 ppm. Des mesures de concentrations d’éthanol dans l’air inhalé générées lors d’utilisation de SHA et de vernis ont permis de simuler des expositions lors de l’utilisation de ces produits. Pour l’utilisation de 1,5 g et 3 g de SHA dans un local peu ventilé, des concentrations sanguines maximales (Cmax) de 0.383 et 0.366 mg.L-1 ont été respectivement simulées. Dans un local bien ventilé, les Cmax simulées étaient de 0.264 et 0.414 mg.L-1. Selon les simulations, une application de vernis résulterait en une Cmax respectivement de 0.719 mg.L-1 et de 0.729 mg.L-1, chez les hommes et femmes. Les Cmax sanguines d’éthanol estimées suites aux différentes simulations sont inférieures à la concentration toxique pour les humains (100 mg.L-1). Ainsi, de telles expositions ne semblent pas être un danger pour la santé. Les résultats de cette étude ont permis de mieux décrire et comprendre les processus d’élimination de l’éthanol à faibles doses et permettront de raffiner l’évaluation du risque associé à l’inhalation chronique de faibles niveaux d’éthanol pour la population, particulièrement chez les travailleurs. / A physiologically based pharmacokinetic model (PBPK) on inhalation exposure to ethanol has previously been developed based on data from an inhalation study in volunteers exposed to more than 5000 ppm. However, there remains uncertainty about the ability of the PBPK model to predict the blood levels of ethanol (BLE) for exposure to low concentrations. These levels are frequently encountered by a large part of the population and workers by using products such as varnishes and alcoholic solutions (HAS). It is therefore necessary to verify the validity of the existing model and determine the internal exposure to ethanol in such conditions. The objectives of this master’s thesis are 1) to document the BLE resulting from inhalation exposure to low concentrations of ethanol (i.e., ≤ 1000 ppm) and validate/refine the existing PBPK model for these concentrations, and 2) to determine the atmospheric concentrations of ethanol following the use of alcoholic solutions (HAS) and varnish as well as to predict the BLE resulting from their use. Toxicokinetic data collected from volunteers suggest that it is insufficient to limit metabolic clearance of ethanol to the liver during exposures to low levels of ethanol, unlike exposures to stronger levels. In addition, it was clearly demonstrated that light exercise (50W) increased (2-3 fold) the BLE in volunteers exposed to 750 ppm. An addition to the PBPK model of a metabolic clearance of high affinity and low capacity associated with richly perfused tissue was performed to simulate more accurately the toxicokinetic data from low and high ethanol exposure levels. Measurements of ethanol concentrations in inhaled air generated during the use of HAS and varnishes were used to simulate the exposure during the use of these products. The simulation for HAS, for 1.5 g and 3 g, gave a maximum blood concentration (Cmax) of 0.383 and 0.366 mg.L-1 respectively in a poorly ventilated room. In a well-ventilated room, the simulated Cmax for 1.5 g and 3 g of HAS were 0.264 and 0.414 mg.L-1, respectively. The simulation results from the use of ethanol-based varnish yielded a Cmax for men and women of 0.719 and 0.729 mg.L-1 respectively. The blood Cmax of ethanol previously listed for the various simulations are well below the toxic dose for humans (50 mg.L-1). Thus, such exposures do not seem to be a health hazard. The results of this study helped to better describe and understand the elimination of ethanol at low doses and refine the evaluation process associated with chronic inhalation of low levels of ethanol to the population risk, particularly in workers.